Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: Possible enhancement of graft-vs-tumor effect [15]

Leukemia

Volumn 19, Issue 9, 2005, Pages 1702-1704

  Paubelle, E ^a   Coppo, P ^a   Garderet, L ^a   Azizi, L ^a   Bories, D ^b   Gorin, N C ^a   Fouillard, Loic ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; BUSULFAN; CALCIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; METHOTREXATE; PARAPROTEIN; PREDNISONE; THALIDOMIDE; VINCRISTINE; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CHIMERA; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOFLUORESCENCE; INFORMED CONSENT; LETTER; LYMPHOCYTE; MALE; MULTIPLE MYELOMA; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SALVAGE THERAPY; TREATMENT FAILURE; FOLLOW UP; MIDDLE AGED; REMISSION; TREATMENT OUTCOME;

BORONIC ACIDS; FOLLOW-UP STUDIES; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; PYRAZINES; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 26944474502     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403855     Document Type: Letter

References (7)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 35: 1860-1873.
2. Stanford BL, Zondor SD. Bortezomib treatment for multiple myeloma. Ann Pharmacother 2003; 37: 1825-1830.
3. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-1534.
4. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
5. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618-4625.
6. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
7. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 12777.